{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:57:07Z","timestamp":1790024227378,"version":"4.0.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["CA148062-01"],"award-info":[{"award-number":["CA148062-01"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1P50 CA174521-01"],"award-info":[{"award-number":["1P50 CA174521-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1245\/s10434-024-16463-7","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T18:02:25Z","timestamp":1730916145000},"page":"1136-1148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors"],"prefix":"10.1245","volume":"32","author":[{"given":"Luis C.","family":"Borbon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Breheny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrikha","family":"Chandrasekharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Menda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bushnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Bellizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. H.","family":"Ear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Sue","family":"O\u2019Dorisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"O\u2019Dorisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5312-5972","authenticated-orcid":false,"given":"James R.","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"issue":"1","key":"16463_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/SLA.0b013e31818e4641","volume":"249","author":"KY Bilimoria","year":"2009","unstructured":"Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009;249(1):63\u201371.","journal-title":"Ann Surg."},{"key":"16463_CR2","unstructured":"Neuroendocrine Tumor of the Pancreas. Available at: https:\/\/www.cancer.net\/cancer-types\/neuroendocrine-tumor-pancreas\/statistics."},{"issue":"18","key":"16463_CR3","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063\u201372.","journal-title":"J Clin Oncol."},{"issue":"10","key":"16463_CR4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342.","journal-title":"JAMA Oncol."},{"issue":"6","key":"16463_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","volume":"46","author":"JR Howe","year":"2017","unstructured":"Howe JR, Cardona K, Fraker DL, et al. The Surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American neuroendocrine tumor society. Pancreas. 2017;46(6):715\u201331.","journal-title":"Pancreas."},{"issue":"1","key":"16463_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MPA.0000000000001454","volume":"49","author":"JR Howe","year":"2020","unstructured":"Howe JR, Merchant NB, Conrad C, et al. The North American neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49(1):1\u201333.","journal-title":"Pancreas."},{"issue":"12","key":"16463_CR7","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1245\/s10434-010-1154-5","volume":"17","author":"SC Mayo","year":"2010","unstructured":"Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17(12):3129\u201336.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"16463_CR8","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","volume":"31","author":"W Bauer","year":"1982","unstructured":"Bauer W, Briner U, Doepfner W, et al. SMS 201\u2013995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982;31(11):1133\u201340.","journal-title":"Life Sci."},{"issue":"11","key":"16463_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1056\/NEJM198609113151102","volume":"315","author":"LK Kvols","year":"1986","unstructured":"Kvols LK, Moertel CG, O\u2019Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315(11):663\u20136.","journal-title":"N Engl J Med."},{"issue":"28","key":"16463_CR10","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656\u201363.","journal-title":"J Clin Oncol."},{"issue":"3","key":"16463_CR11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224\u201333.","journal-title":"N Engl J Med."},{"issue":"6","key":"16463_CR12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514\u201323.","journal-title":"N Engl J Med."},{"issue":"10022","key":"16463_CR13","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968\u201377.","journal-title":"Lancet."},{"issue":"6","key":"16463_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501\u201313.","journal-title":"N Engl J Med."},{"issue":"16 Suppl","key":"16463_CR15","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.2022.40.16_suppl.4004","volume":"40","author":"PL Kunz","year":"2022","unstructured":"Kunz PL, Graham N, Catalano PJ, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211). J Clin Oncol. 2022;40(16 Suppl):4004.","journal-title":"J Clin Oncol."},{"issue":"2","key":"16463_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med."},{"issue":"11","key":"16463_CR17","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1245\/s10434-022-12149-0","volume":"29","author":"JR Howe","year":"2022","unstructured":"Howe JR. Sequencing of therapies in progressive neuroendocrine tumors. Ann Surg Oncol. 2022;29(11):6501\u20133.","journal-title":"Ann Surg Oncol."},{"issue":"Suppl 1","key":"16463_CR18","first-page":"62S","volume":"46","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(Suppl 1):62S-66S.","journal-title":"J Nucl Med."},{"issue":"12","key":"16463_CR19","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, et al. (177)Lu-Dotatate plus long-acting octreotide versus highdose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1752\u201363.","journal-title":"Lancet Oncol."},{"issue":"2","key":"16463_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer."},{"key":"16463_CR21","unstructured":"Klimstra D, Kl\u00f6ppel G, La Rosa S, Rindi G. WHO Classification of neuroendocrine neoplasms of the digestive system. WHO Classification of tumours. Digestive system tumours. 5th ed. Lyon: IARC Press; 2019. pp. 16-19."},{"issue":"2","key":"16463_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/PAS.0b013e31823d07f3","volume":"36","author":"M Korner","year":"2012","unstructured":"Korner M, Waser B, Schonbrunn A, Perren A, Reubi JC. Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am J Surg Pathol. 2012;36(2):242\u201352.","journal-title":"Am J Surg Pathol."},{"issue":"2","key":"16463_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/PAI.0000000000000563","volume":"26","author":"TW Czeczok","year":"2018","unstructured":"Czeczok TW, Stashek KM, Maxwell JE, et al. Clusterin in neuroendocrine epithelial neoplasms: absence of expression in a well-differentiated tumor suggests a jejunoileal origin. Appl Immunohistochem Mol Morphol. 2018;26(2):94\u2013100.","journal-title":"Appl Immunohistochem Mol Morphol."},{"issue":"Suppl 2","key":"16463_CR24","first-page":"S219","volume":"31","author":"EP Krenning","year":"1999","unstructured":"Krenning EP, Valkema R, Kooij PP, et al. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. Ital J Gastroenterol Hepatol. 1999;31(Suppl 2):S219-223.","journal-title":"Ital J Gastroenterol Hepatol."},{"issue":"9","key":"16463_CR25","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.2967\/jnumed.118.223016","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Calais J, Zhang L, Dieckmann W, Millo C. (111)In-pentetreotide scintigraphy versus (68)Ga-DOTATATE PET: impact on krenning scores and effect of tumor burden. J Nucl Med. 2019;60(9):1266\u20139.","journal-title":"J Nucl Med."},{"key":"16463_CR26","volume-title":"AJCC Cancer Staging Manual","author":"MB Amin","year":"2017","unstructured":"Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. 8th edn. Springer; 2017.","edition":"8"},{"issue":"1","key":"16463_CR27","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.surg.2018.04.070","volume":"165","author":"AT Scott","year":"2019","unstructured":"Scott AT, Breheny PJ, Keck KJ, et al. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery. 2019;165(1):166\u201375.","journal-title":"Surgery."},{"issue":"6","key":"16463_CR28","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.surg.2014.08.009","volume":"156","author":"AN Graff-Baker","year":"2014","unstructured":"Graff-Baker AN, Sauer DA, Pommier SJ, Pommier RF. Expanded criteria for carcinoid liver debulking: Maintaining survival and increasing the number of eligible patients. Surgery. 2014;156(6):1369\u201376.","journal-title":"Surgery."},{"issue":"1","key":"16463_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.surg.2017.05.030","volume":"163","author":"RE Morgan","year":"2018","unstructured":"Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery. 2018;163(1):218\u201325.","journal-title":"Surgery."},{"issue":"2","key":"16463_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/SLA.0b013e3181bdf8cf","volume":"251","author":"D Elias","year":"2010","unstructured":"Elias D, Lefevre JH, Duvillard P, et al. Hepatic metastases from neuroendocrine tumors with a \u201cthin slice\u201d pathological examination: they are many more than you think. Ann Surg. 2010;251(2):307\u201310.","journal-title":"Ann Surg."},{"key":"16463_CR31","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1749-6632.1994.tb17300.x","volume":"733","author":"EP Krenning","year":"1994","unstructured":"Krenning EP, Kooij PP, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide: a case history. Ann N Y Acad Sci. 1994;733:496\u2013506.","journal-title":"Ann N Y Acad Sci."},{"issue":"2","key":"16463_CR32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","volume":"32","author":"R Valkema","year":"2002","unstructured":"Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32(2):110\u201322.","journal-title":"Semin Nucl Med."},{"issue":"2","key":"16463_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1053\/snuc.2002.31769","volume":"32","author":"LB Anthony","year":"2002","unstructured":"Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32(2):123\u201332.","journal-title":"Semin Nucl Med."},{"issue":"11","key":"16463_CR34","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s002590050476","volume":"26","author":"A Otte","year":"1999","unstructured":"Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26(11):1439\u201347.","journal-title":"Eur J Nucl Med."},{"issue":"7","key":"16463_CR35","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1023\/A:1011160913619","volume":"12","author":"C Waldherr","year":"2001","unstructured":"Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12(7):941\u20135.","journal-title":"Ann Oncol."},{"issue":"17","key":"16463_CR36","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","volume":"29","author":"A Imhof","year":"2011","unstructured":"Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416\u201323.","journal-title":"J Clin Oncol."},{"issue":"9","key":"16463_CR37","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s002590100574","volume":"28","author":"DJ Kwekkeboom","year":"2001","unstructured":"Kwekkeboom DJ, Bakker WH, Kooij PP, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001;28(9):1319\u201325.","journal-title":"Eur J Nucl Med."},{"issue":"12","key":"16463_CR38","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","volume":"23","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23(12):2754\u201362.","journal-title":"J Clin Oncol."},{"issue":"13","key":"16463_CR39","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124\u201330.","journal-title":"J Clin Oncol."},{"key":"16463_CR40","volume-title":"FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETS","author":"US Fda","year":"2018","unstructured":"Fda US. FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETS. Silver; 2018."},{"issue":"8","key":"16463_CR41","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00259-013-2402-2","volume":"40","author":"D Campana","year":"2013","unstructured":"Campana D, Capurso G, Partelli S, et al. Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. Eur J Nucl Med Mol Imaging. 2013;40(8):1197\u2013205.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"2","key":"16463_CR42","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2967\/jnumed.113.125336","volume":"55","author":"S Ezziddin","year":"2014","unstructured":"Ezziddin S, Attassi M, Yong-Hing CJ, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2014;55(2):183\u201390.","journal-title":"J Nucl Med."},{"issue":"10","key":"16463_CR43","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1007\/s00259-020-04709-x","volume":"47","author":"J Strosberg","year":"2020","unstructured":"Strosberg J, Kunz PL, Hendifar A, et al. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nuclear Med Mol Imaging. 2020;47(10):2372\u201382.","journal-title":"Eur J Nuclear Med Mol Imaging."},{"issue":"10","key":"16463_CR44","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","volume":"28","author":"DL Bushnell Jr","year":"2010","unstructured":"Bushnell DL Jr, O\u2019Dorisio TM, O\u2019Dorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28(10):1652\u20139.","journal-title":"J Clin Oncol."},{"issue":"2","key":"16463_CR45","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/MPA.0000000000000734","volume":"46","author":"N Sharma","year":"2017","unstructured":"Sharma N, Naraev BG, Engelman EG, et al. Peptide receptor radionuclide therapy outcomes in a North American cohort with metastatic well-differentiated neuroendocrine tumors. Pancreas. 2017;46(2):151\u20136.","journal-title":"Pancreas."},{"issue":"Suppl 5","key":"16463_CR46","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1245\/s10434-016-5550-3","volume":"23","author":"E Bertani","year":"2016","unstructured":"Bertani E, Fazio N, Radice D, et al. Resection of the Primary tumor followed by peptide receptor radionuclide therapy as upfront strategy for the treatment of G1\u2013G2 pancreatic neuroendocrine tumors with unresectable liver metastases. Ann Surg Oncol. 2016;23(Suppl 5):981\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"16463_CR47","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/SLA.0000000000003237","volume":"274","author":"D Kaemmerer","year":"2021","unstructured":"Kaemmerer D, Twrznik M, Kulkarni HR, et al. Prior resection of the primary tumor prolongs survival after peptide receptor radionuclide therapy of advanced neuroendocrine neoplasms. Ann Surg. 2021;274(1):e45\u201353.","journal-title":"Ann Surg."},{"issue":"2","key":"16463_CR48","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0290","volume":"5","author":"S Pusceddu","year":"2022","unstructured":"Pusceddu S, Prinzi N, Tafuto S, et al. Association of upfront peptide receptor radionuclide therapy with progression-free survival among patients with enteropancreatic neuroendocrine tumors. JAMA Netw Open. 2022;5(2):e220290.","journal-title":"JAMA Netw Open."},{"issue":"8 Suppl","key":"16463_CR49","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1016\/j.jclinepi.2013.01.014","volume":"66","author":"X Mi","year":"2013","unstructured":"Mi X, Hammill BG, Curtis LH, Greiner MA, Setoguchi S. Impact of immortal person-time and time scale in comparative effectiveness research for medical devices: a case for implantable cardioverter-defibrillators. J Clin Epidemiol. 2013;66(8 Suppl):S138\u201344.","journal-title":"J Clin Epidemiol"},{"key":"16463_CR50","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jcrc.2016.07.017","volume":"36","author":"M Jones","year":"2016","unstructured":"Jones M, Fowler R. Immortal time bias in observational studies of time-to-event outcomes. J Crit Care. 2016;36:195\u20139.","journal-title":"J Crit Care."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16463-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16463-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16463-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T18:02:03Z","timestamp":1735927323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16463-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["16463"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16463-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}